Laboratory of Experimental and Cellular Medicine, Moscow Institute of Physics and Technology, Institutskiy Lane 9, 141700 Dolgoprudny, Russia.
M.F. Vladimirsky Moscow Regional Clinical Research Institute, Schepkina St. 61/2, 129110 Moscow, Russia.
Int J Mol Sci. 2023 Jun 20;24(12):10406. doi: 10.3390/ijms241210406.
Myocardial remodeling is an inevitable risk factor for cardiac arrhythmias and can potentially be corrected with cell therapy. Although the generation of cardiac cells ex vivo is possible, specific approaches to cell replacement therapy remain unclear. On the one hand, adhesive myocyte cells must be viable and conjugated with the electromechanical syncytium of the recipient tissue, which is unattainable without an external scaffold substrate. On the other hand, the outer scaffold may hinder cell delivery, for example, making intramyocardial injection difficult. To resolve this contradiction, we developed molecular vehicles that combine a wrapped (rather than outer) polymer scaffold that is enveloped by the cell and provides excitability restoration (lost when cells were harvested) before engraftment. It also provides a coating with human fibronectin, which initiates the process of graft adhesion into the recipient tissue and can carry fluorescent markers for the external control of the non-invasive cell position. In this work, we used a type of scaffold that allowed us to use the advantages of a scaffold-free cell suspension for cell delivery. Fragmented nanofibers (0.85 µm ± 0.18 µm in diameter) with fluorescent labels were used, with solitary cells seeded on them. Cell implantation experiments were performed in vivo. The proposed molecular vehicles made it possible to establish rapid (30 min) electromechanical contact between excitable grafts and the recipient heart. Excitable grafts were visualized with optical mapping on a rat heart with Langendorff perfusion at a 0.72 ± 0.32 Hz heart rate. Thus, the pre-restored grafts' excitability (with the help of a wrapped polymer scaffold) allowed rapid electromechanical coupling with the recipient tissue. This information could provide a basis for the reduction of engraftment arrhythmias in the first days after cell therapy.
心肌重构是心律失常不可避免的危险因素,通过细胞治疗可能得到纠正。虽然体外生成心肌细胞是可能的,但细胞替代治疗的具体方法仍不清楚。一方面,黏附心肌细胞必须是有活力的,并与受体组织的机电同步连接,如果没有外部支架基质,这是不可能的。另一方面,外部支架可能会阻碍细胞的传递,例如,使心肌内注射变得困难。为了解决这一矛盾,我们开发了分子载体,将包裹(而不是外部)聚合物支架与细胞结合,在移植前提供兴奋性恢复(细胞收获时丧失)。它还提供了一种带有人类纤维连接蛋白的涂层,启动了移植物进入受体组织的附着过程,并可以携带荧光标记物,用于对外来细胞位置的非侵入性控制。在这项工作中,我们使用了一种支架,使我们能够利用无支架细胞悬浮液的优势来进行细胞传递。使用带有荧光标记的碎片化纳米纤维(直径 0.85 µm ± 0.18 µm),并在其上接种单细胞。进行了体内细胞植入实验。所提出的分子载体使得兴奋性移植物与受体心脏之间能够快速(30 分钟)建立机电接触。在 Langendorff 灌流的大鼠心脏上进行光学映射,观察到具有 0.72 ± 0.32 Hz 心率的可兴奋移植物。因此,在受体组织中,预先恢复的移植物的兴奋性(在包裹聚合物支架的帮助下)允许与受体组织快速建立机电耦联。这些信息可能为减少细胞治疗后最初几天的移植心律失常提供依据。